Kaiser Permanente contributed to a round that pushed the total raised by the ceullar cancer therapy developer to $300m.

US-based cell therapy developer Orca Bio secured $192m on Wednesday in a series D round featuring healthcare provider Kaiser Permanente’s Group Trust as well as its Kaiser Foundation Hospitals subsidiary. Venture capital firm Lightspeed Venture Partners co-led the round with an unnamed additional investor, while 8VC, Data Collective’s DCVC Bio unit, ND Capital, the Abu…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.